Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$11.55 USD
+0.03 (0.26%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $11.35 -0.20 (-1.73%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Return on Equity (TTM)
Atara Biotherapeutics, Inc.'s return on equity, or ROE, is -783.31% compared to the ROE of the Medical - Biomedical and Genetics industry of -64.16%. While this shows that ATRA has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ATRA 11.55 +0.03(0.26%)
Will ATRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATRA
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates
ATRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus
Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
Other News for ATRA
Atara Biotherapeutics (ATRA) Shares Surge After Priority Review Grant
Atara gets FDA priority review for Tabelecleucel application
Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics ...
FDA Accepts Atara Biotherapeutics' BLA for Tabelecleucel (ATRA) | ATRA Stock News
Atara Biotherapeutics announces FDA acceptance of tabelecleucel BLA